9 7 3 1 8
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
已发表论文
RASSF1A 启动子甲基化与甲状腺癌的风险增加相关联：一项综合分析
Authors Shou FY, Xu F, Li G, Zhao ZH, Mao Y, Yang FF, Wang HM, Guo HY
Received 11 October 2016
Accepted for publication 8 November 2016
Published 9 January 2017 Volume 2017:10 Pages 247—257
DOI https://doi.org/10.2147/OTT.S124417
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Narasimha Reddy Parine
Peer reviewer comments 2
Editor who approved publication: Dr Ingrid Espinoza
Objective: Previous studies have
reported that Ras-associated domain family 1A (RASSF1A), the most commonly
silenced tumor suppressor via promoter methylation, played vital roles in the
development of carcinogenesis. The purpose of this meta-analysis was to
determine whether RASSF1A promoter methylation increased the risk of thyroid
cancer.
Methods: PubMed, Embase, ISI Web of Knowledge, and Chinese National Knowledge Infrastructure databases were searched to obtain eligible studies. The pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the strength of the associations, using Stata 12.0 software. The methodological quality of included studies was evaluated using Newcastle–Ottawa scale table. Egger’s test and Begg’s test were applied to detect publication biases. TSA 0.9 software was used to calculate the required information size and whether the result was conclusive.
Results: A total of 10 articles with 12 studies that included 422 thyroid cancer patients, identifying the association of RASSF1A promoter methylation with thyroid cancer risk, were collected in this meta-analysis. Overall, RASSF1A promoter methylation significantly increased the risk of thyroid cancer (total, OR=8.27, CI=4.38–15.62, P <0.05; Caucasian, OR=9.25, CI=3.97–21.56, P <0.05; Asian, OR=7.01, CI=2.68–18.38, P <0.05). In the subgroup analysis based on sample type, a significant association between thyroid cancer group and control group was found (normal tissue, OR=9.55, CI=4.21–21.67, P <0.05; adjacent tissue, OR=6.80, CI=2.49–18.56, P <0.05). The frequency of RASSF1A promoter methylation in follicular thyroid carcinoma was higher than in control group (OR=11.88, CI=5.80–24.32, P <0.05). In addition, the results indicated that the RASSF1A promoter methylation was correlated with papillary thyroid carcinoma in Caucasians and Asians (total, OR=8.07, CI=3.54–18.41, P <0.05; Caucasian, OR=11.35, CI=2.39–53.98, P <0.05; Asian, OR=6.67, CI=2.53–17.64, P <0.05). On the basis of the trial sequential analysis, the significant association of RASSF1A promoter methylation with thyroid cancer risk was found, and there was no need to perform further studies.
Conclusion: This meta-analysis confirms that RASSF1A promoter methylation is a risk factor for thyroid tumor.
Keywords: RASSF1A, methylation, thyroid neoplasms, meta-analysis
Methods: PubMed, Embase, ISI Web of Knowledge, and Chinese National Knowledge Infrastructure databases were searched to obtain eligible studies. The pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the strength of the associations, using Stata 12.0 software. The methodological quality of included studies was evaluated using Newcastle–Ottawa scale table. Egger’s test and Begg’s test were applied to detect publication biases. TSA 0.9 software was used to calculate the required information size and whether the result was conclusive.
Results: A total of 10 articles with 12 studies that included 422 thyroid cancer patients, identifying the association of RASSF1A promoter methylation with thyroid cancer risk, were collected in this meta-analysis. Overall, RASSF1A promoter methylation significantly increased the risk of thyroid cancer (total, OR=8.27, CI=4.38–15.62, P <0.05; Caucasian, OR=9.25, CI=3.97–21.56, P <0.05; Asian, OR=7.01, CI=2.68–18.38, P <0.05). In the subgroup analysis based on sample type, a significant association between thyroid cancer group and control group was found (normal tissue, OR=9.55, CI=4.21–21.67, P <0.05; adjacent tissue, OR=6.80, CI=2.49–18.56, P <0.05). The frequency of RASSF1A promoter methylation in follicular thyroid carcinoma was higher than in control group (OR=11.88, CI=5.80–24.32, P <0.05). In addition, the results indicated that the RASSF1A promoter methylation was correlated with papillary thyroid carcinoma in Caucasians and Asians (total, OR=8.07, CI=3.54–18.41, P <0.05; Caucasian, OR=11.35, CI=2.39–53.98, P <0.05; Asian, OR=6.67, CI=2.53–17.64, P <0.05). On the basis of the trial sequential analysis, the significant association of RASSF1A promoter methylation with thyroid cancer risk was found, and there was no need to perform further studies.
Conclusion: This meta-analysis confirms that RASSF1A promoter methylation is a risk factor for thyroid tumor.
Keywords: RASSF1A, methylation, thyroid neoplasms, meta-analysis
